AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 14 |
Market Cap | 454.60M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -6.05 |
PE Ratio (ttm) | -2.47 |
Forward PE | n/a |
Analyst | Buy |
Ask | 22 |
Volume | 641,650 |
Avg. Volume (20D) | 629,673 |
Open | 14.77 |
Previous Close | 14.62 |
Day's Range | 14.37 - 15.63 |
52-Week Range | 12.51 - 41.31 |
Beta | undefined |
About ANAB
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress...
Analyst Forecast
According to 11 analyst ratings, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 154.35% from the latest price.
Next Earnings Release
Analysts project revenue of $10.09M, reflecting a 12.05% YoY growth and earnings per share of -1.74, making a 9.43% increase YoY.